Ceramide Biomarker Prediction for Radiation Therapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for determining radiation therapy efficacy in cancer treatment are delayed and lack reliable biomarkers to differentiate between responding and refractory patients, hindering timely alternative treatment decisions.
Innovation Solution
The method involves measuring ceramide levels in patient plasma before and after radiation therapy, specifically focusing on the fold change of ceramide concentrations to predict treatment response, using LC-MS/MS analysis to correlate ceramide elevation with tumor control in patients undergoing hypofractionated radiation therapy combined with irinotecan.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tumor volume control is visualized by CT-scan or non-invasive imaging techniques, then radiation therapy efficacy can be assessed, but the evaluation is delayed by months after treatment ends
Solution Approach 1:
The patent measures ceramide levels in plasma before radiation therapy begins (baseline measurement) and during treatment, enabling early prediction of treatment response before months pass. This preliminary biomarker assessment allows clinicians to forecast efficacy outcomes in advance rather than waiting for delayed imaging results
Solution Approach 2:
The patent replaces the mechanical/imaging-based assessment system (CT-scan, MRI) with a biochemical measurement system (ceramide level analysis). This substitution uses molecular biomarkers in plasma to predict treatment response, replacing the need for delayed structural imaging with immediate biochemical evaluation
2Measurement precision
If tumor biopsies are performed to obtain omics biomarkers, then a broad range of molecular events can be analyzed, but the studies are limited to specific tumor localisation and the number of samples
Solution Approach 1:
The patent uses plasma as an intermediary medium that reflects tumor biology without requiring direct tumor sampling. Ceramide levels in plasma serve as a mediator that provides molecular information about tumor response to radiation therapy, bypassing the limitations of biopsy-based approaches while maintaining measurement precision
Solution Approach 2:
The patent applies a universal biomarker approach where plasma ceramide levels can be measured regardless of tumor location or type. This single biomarker system works across different tumor localizations and patient populations, providing versatile applicability that biopsy-based omics approaches cannot achieve
3Ease of operation
If phenotypic imaging is used to evaluate tumor physiology, then non-invasive assessment of hypoxia, cell proliferation, and immune cell infiltration is possible, but consistent quantification of molecular biomarkers remains under investigation
Solution Approach 1:
The patent shifts the measurement parameter from structural/physiological imaging parameters (hypoxia, cell proliferation indices) to a specific biochemical parameter (ceramide concentration). This parameter change enables precise quantitative measurement of a molecular biomarker in plasma that directly correlates with radiation therapy response, achieving both non-invasive evaluation and measurement precision
4Ease of operation
If secretory factors from blood samples are measured, then easy sample collection is achieved, but none have been validated as biomarkers of radiation therapy efficacy
Solution Approach 1:
The patent identifies and measures specific ceramide species (d18:1/16:0, d18:1/18:0, d18:1/20:4, d18:1/22:6) in plasma as the reliable biomarker parameter. This specific parameter selection transforms an unvalidated approach into a validated biomarker system that reliably predicts radiation therapy response while maintaining the ease of blood sample collection
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for early discrimination between responders and non-responders, enabling timely adaptation of treatment protocols and reducing adverse effects by identifying ceramide as a reliable biomarker for radiation therapy efficacy.
Implementation Method 1
using LC-MS/MS analysis to correlate ceramide elevation with tumor control
Data Source
AI summary
Disclosed are methods for determining whether a patient will achieve a response after radiation therapy, in particular a method for determining whether a patient suffering from a cancer will achieve a response after radiation therapy including the steps of i) determining the level of ceramide in a first blood sample obtained from the patient before radiation therapy, ii) determining the level of ceramide in a second blood sample obtained from the patient during or just after radiation therapy, iii) comparing the level determined at step i) with the level determined at step ii) and iv) concluding that the patient will achieve response when the level determined at step ii) is higher than the level determined at step i) or concluding that the patient will not achieve a response when the level determined at step ii) is lower than the level determined at step i).